Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) stock fell -5.59% on Friday to $52.32 against a previous-day closing price of $55.42. With 1.43 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.53 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $54.47 whereas the lowest price it dropped to was $49.31. The 52-week range on HRMY shows that it touched its highest point at $57.13 and its lowest point at $26.06 during that stretch. It currently has a 1-year price target of $59.62.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HRMY was up-trending over the past week, with a rise of 2.07%, but this was down by -0.63% over a month. Three-month performance surged to 40.72% while six-month performance rose 39.30%. The stock gained 92.57% in the past year, while it has gained 22.70% so far this year. A look at the trailing 12-month EPS for HRMY yields 0.80 with Next year EPS estimates of 3.18. For the next quarter, that number is 0.44. This implies an EPS growth rate of 152.10% for this year and 72.15% for next year.
Float and Shares Shorts:
At present, 58.91 million HRMY shares are outstanding with a float of 47.17 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.68 million, which was 7.92% higher than short shares on Jun 14, 2022. In addition to Mr. Jeffrey S. Aronin as the firm’s Founder & Non-Exec. Chairman, Mr. John Charles Jacobs M.B.A. serves as its Pres, CEO & Director.
Through their ownership of 86.22% of HRMY’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 49.75% of HRMY, in contrast to 34.63% held by mutual funds. Shares owned by individuals account for 17.51%. As the largest shareholder in HRMY with 8.29% of the stake, Fidelity Management & Research Co holds 4,897,004 shares worth 4,897,004. A second-largest stockholder of HRMY, HBM Partners AG, holds 3,663,228 shares, controlling over 6.20% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in HRMY, holding 3,350,939 shares or 5.68% stake. With a 6.20% stake in HRMY, the HBM Healthcare Investments is the largest stakeholder. A total of 3,663,228 shares are owned by the mutual fund manager. The Fidelity Growth Company Fund, which owns about 3.14% of HRMY stock, is the second-largest Mutual Fund holder. It holds 1,852,117 shares valued at 90.33 million. iShares Core S&P Small Cap ETF holds 2.76% of the stake in HRMY, owning 1,629,913 shares worth 79.49 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HRMY since 8 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HRMY analysts setting a high price target of $64.00 and a low target of $56.00, the average target price over the next 12 months is $59.63. Based on these targets, HRMY could surge 22.32% to reach the target high and rise by 7.03% to reach the target low. Reaching the average price target will result in a growth of 13.97% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. HRMY will report FY 2022 earnings on 03/23/2023. Analysts have provided yearly estimates in a range of $2.46 being high and $1.34 being low. For HRMY, this leads to a yearly average estimate of $1.95. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Harmony Biosciences Holdings Inc. surprised analysts by $0.09 when it reported $0.57 EPS against a consensus estimate of $0.48. The surprise factor in the prior quarter was $0.22. Based on analyst estimates, the high estimate for the next quarter is $0.63 and the low estimate is $0.33. The average estimate for the next quarter is thus $0.48.
Summary of Insider Activity:
Insiders traded HRMY stock several times over the past three months with 2 Buys and 16 Sells. In these transactions, 40,000 shares were bought while 512,403 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has risen to 99 over the past year. The total number of shares bought during that period was 531,837 while 2,230,115 shares were sold.